Regeneron
Tarrytown, New York, United States · Biotechnology, Health Care, Science And Engineering
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown
Key facts
- Headquarters
- Tarrytown, New York, United States
- Employees
- 17,048
- Industries
- Biotechnology, Health Care, Science And Engineering
- Status
- Public (REGN)
- Website
- www.regeneron.com
Recent activity at Regeneron
- : Regeneron partners with Parabilis to develop a new class of drug worth up to $2.3 billion.
- : Regeneron Pharmaceuticals Expands U.S. Capacity With US$3 Billion Fujifilm Partnership
- : Regeneron Pharmaceuticals Achieves Sixth Year on Dow Jones Sustainability World Index Reflecting Commitment to Responsible Practices
- : Regeneron Completes Acquisition Of Decibel Therapeutics, Adding Promising Gene Therapy Programs For Hearing Loss
- : Regeneron To Acquire Decibel Therapeutics, Strengthening Gene Therapy And Hearing Loss Programs
- : Regeneron Completes Acquisition Of Checkmate Pharmaceuticals
- : Regeneron To Acquire Checkmate Pharmaceuticals And Its Investigational Immune Activator For Potential Use In Multiple Tumor Types
Employee benefit plans
Regeneron files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Regeneron in the news
- Regeneron and Telix Announce Strategic Radiopharma Collaboration - Regeneron (Apr 13, 2026)
- Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - Regeneron (Apr 02, 2026)
- Regeneron Announces Investor Conference Presentations - The Manila Times (Nov 02, 2026)
- Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results - Regeneron (Feb 02, 2024)
- Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Regeneron (Feb 03, 2023)
Companies similar to Regeneron
- Gilead Sciences · Biotechnology, Health Care, Therapeutics
- Conagra Brands · Biotechnology, Health Care, Science And Engineering
- Charles River Laboratories · Biotechnology, Health Care, Science And Engineering
- Genentech · Biotechnology, Health Care, Therapeutics
- Chugai Pharmaceutical · Biotechnology, Health Care, Therapeutics
About Regeneron: questions and answers
What does Regeneron do?
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown
Where is Regeneron headquartered?
Regeneron is headquartered in Tarrytown, New York, United States.
How many employees does Regeneron have?
Regeneron has about 17,048 employees.
What is the latest news on Regeneron?
On May 18, 2026, Regeneron partners with Parabilis to develop a new class of drug worth up to $2.3 billion.
Is Regeneron a public company?
Yes. Regeneron is publicly traded under the ticker REGN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy